Cricket-derived fiber met tolerability criteria in a small IBS pilot
Both study treatments were followed by improved digestive symptoms. The chitin treatment also showed a difference in a blood inflammation marker.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pilot met its safety and tolerability criteria, and participants reported improved digestive symptoms after both treatments. Chitin also lowered a blood inflammation marker more than the comparator. This small study provides preliminary evidence about tolerability and biological changes; it does not establish that chitin provides greater symptom relief than the comparison treatment.
This was a small pilot designed partly to inform future trials. The abstract reports different significance levels for symptom changes within each treatment, which cannot establish a difference in symptom benefit between treatments.
What researchers found
Serum TNF-alpha, an inflammatory biomarker
Chitin versus maltodextrin after 30-day treatment periods; the reported between-treatment difference was statistically significant.
Why the crossover matters
Participants received both treatments in sequence, with a washout between them. The main question concerned safety and tolerability, while digestive symptoms, inflammatory markers and gut microbes were additional exploratory outcomes.
Symptoms and markers are different
A lower blood inflammatory marker is a biological finding, not direct proof of less pain or better daily functioning. The symptom results need their own comparison before claiming that chitin outperformed the alternative.
The original publication
Safety, tolerability, and preliminary effects of cricket chitin for adults with IBS: a double-blind randomized crossover pilot trial.
Vita AA, Teo S, Murphy C et al.
Food Funct · 2025
- PubMed ID
- 40891151
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.